A Study of TAK-861 in Participants With Narcolepsy Type 2
Status:
Not yet recruiting
Trial end date:
2024-10-05
Target enrollment:
Participant gender:
Summary
The main aim is to evaluate the effect of TAK-861 on symptoms of narcolepsy, including
excessive daytime sleepiness (EDS) as measured by sleep latency from the Maintenance of
Wakefulness Test (MWT).
The study will enroll approximately 60 participants and they will be randomly assigned to 3
groups (20 per group) to take one of two different doses of TAK-861 or a placebo. All the
participants will receive the treatment for 8 weeks. Participants will be asked to complete
some questionnaires during the study. This trial will be conducted in North America, Europe,
and Asia Pacific.